JP2011190199A - 関節リウマチ薬 - Google Patents
関節リウマチ薬 Download PDFInfo
- Publication number
- JP2011190199A JP2011190199A JP2010056428A JP2010056428A JP2011190199A JP 2011190199 A JP2011190199 A JP 2011190199A JP 2010056428 A JP2010056428 A JP 2010056428A JP 2010056428 A JP2010056428 A JP 2010056428A JP 2011190199 A JP2011190199 A JP 2011190199A
- Authority
- JP
- Japan
- Prior art keywords
- rheumatoid arthritis
- mtx
- bed
- day
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 24
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims abstract description 40
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 229960000485 methotrexate Drugs 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims description 20
- 208000024891 symptom Diseases 0.000 abstract description 12
- 230000001629 suppression Effects 0.000 abstract 1
- 230000009266 disease activity Effects 0.000 description 15
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 230000027288 circadian rhythm Effects 0.000 description 7
- 235000021152 breakfast Nutrition 0.000 description 6
- 230000004044 response Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010023232 Joint swelling Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010056428A JP2011190199A (ja) | 2010-03-12 | 2010-03-12 | 関節リウマチ薬 |
| PCT/JP2010/007262 WO2011111143A1 (ja) | 2010-03-12 | 2010-12-15 | 関節リウマチ薬 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010056428A JP2011190199A (ja) | 2010-03-12 | 2010-03-12 | 関節リウマチ薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011190199A true JP2011190199A (ja) | 2011-09-29 |
| JP2011190199A5 JP2011190199A5 (enExample) | 2013-04-25 |
Family
ID=44562991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010056428A Pending JP2011190199A (ja) | 2010-03-12 | 2010-03-12 | 関節リウマチ薬 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2011190199A (enExample) |
| WO (1) | WO2011111143A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016201069A1 (en) | 2015-06-09 | 2016-12-15 | Danisco Us Inc | Low-density enzyme-containing particles |
| WO2016201040A1 (en) | 2015-06-09 | 2016-12-15 | Danisco Us Inc. | Water-triggered enzyme suspension |
| EP3307427B1 (en) | 2015-06-09 | 2023-08-16 | Danisco US Inc. | Osmotic burst encapsulates |
| US20200040283A1 (en) | 2017-03-31 | 2020-02-06 | Danisco Us Inc | Delayed release enzyme formulations for bleach-containing detergents |
| JP7680825B2 (ja) | 2017-06-30 | 2025-05-21 | ダニスコ・ユーエス・インク | 低凝集の酵素含有粒子 |
| WO2019125683A1 (en) | 2017-12-21 | 2019-06-27 | Danisco Us Inc | Enzyme-containing, hot-melt granules comprising a thermotolerant desiccant |
| EP3749107A1 (en) | 2018-02-08 | 2020-12-16 | Danisco US Inc. | Thermally-resistant wax matrix particles for enzyme encapsulation |
| US20210189295A1 (en) | 2018-08-30 | 2021-06-24 | Danisco Us Inc | Enzyme-containing granules |
| LT3773558T (lt) * | 2019-05-10 | 2022-09-12 | Synact Pharma Aps | Kompleksinis artrito gydymas |
| WO2022268825A1 (en) | 2021-06-21 | 2022-12-29 | Synact Pharma Aps | Phenyl pyrrole aminoguanidine salts and formulations |
| CN117957318A (zh) | 2021-09-13 | 2024-04-30 | 丹尼斯科美国公司 | 含有生物活性物质的颗粒 |
-
2010
- 2010-03-12 JP JP2010056428A patent/JP2011190199A/ja active Pending
- 2010-12-15 WO PCT/JP2010/007262 patent/WO2011111143A1/ja not_active Ceased
Non-Patent Citations (3)
| Title |
|---|
| JPN6011003260; 藤秀人: '抗リウマチ薬の時間薬物療法を目指して' 週刊薬事新報 Ｎｏ．２６１０, 20100101, ｐ．６-１２ * |
| JPN6011003261; 藤秀人: '抗リウマチ薬の時間治療への展望' 時間生物学 Ｖｏｌ．１５， Ｎｏ．２, 2009, ｐ．３３-３９ * |
| JPN6011003262; ＴＯ，Ｈ． ｅｔ ａｌ: Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ ｐｈａｒｍａｃｙ ａｎｄ ｐｈａｒｍａｃｏｌｏｇｙ Ｖｏｌ．６１， Ｎｏ．１０, 2009, ｐ．１３３３-８ * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011111143A1 (ja) | 2011-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011190199A (ja) | 関節リウマチ薬 | |
| JP6837486B2 (ja) | 加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法 | |
| JP2013521303A5 (enExample) | ||
| EP4249490A2 (en) | Methods for treating heterotopic ossification | |
| EA034864B1 (ru) | Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой | |
| JPWO2002074318A1 (ja) | Ｉｌ−１２発現調節剤 | |
| CN105517631A (zh) | 左西替利嗪和孟鲁司特在治疗创伤性损伤中的用途 | |
| Daubländer et al. | Effectiveness and safety of phentolamine mesylate in routine dental care | |
| Mallhi et al. | Chloroquine and hydroxychloroquine in COVID-19: practice implications for healthcare professionals | |
| EP2969001A1 (en) | Use of levocetirizine and montelukast in the treatment of anaphylaxis | |
| Low et al. | Steroids in maxillofacial space infection: A retrospective cohort study | |
| Bhansing et al. | Gout: a clinical syndrome illustrated and discussed. | |
| Farshidi et al. | Lingual hyperpigmentation from pegylated interferon and ribavirin treatment of hepatitis C | |
| MD3752141T2 (ro) | Acetilleucină pentru utilizare în tratarea sindromului picioarelor neliniștite | |
| EP3323416B1 (en) | Pharmaceutical composition for treating premature ejaculation | |
| Askanase et al. | pos1147 efficacy of cenerimod in patients with high ifn-1 gene expression signature and high anti-dsdna antibody levels: post-hoc analysis from a phase 2 study | |
| JPWO2020234781A5 (enExample) | ||
| Chidambaram | Optimal antibiotic dosage for chronic kidney disease patient: a pharmacological manual for oral clinicians | |
| Münzel et al. | Relapsing-remitting multiple sclerosis and chronic idiopathic neutropenia: a challenging combination | |
| IE20130078A1 (en) | Methods for using thalidomide and thalidomide analogues to maintain or increase muscle mass in treating sarcopenia | |
| Viktorova et al. | Course patterns and patient management with joint hypermobility syndrome in the post-COVID-19 period | |
| Rovere-Querini et al. | POS1146 LOW MOLECULAR WEIGHT HEPARINS INTERFERE WITH NEUTROPHIL ACTIVATION AND NET GENERATION IN HIGH-RISK PREGNANT PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME | |
| Anugrah et al. | Complications of Recurrent Corticosteroid Use in Patients with Erythema Nodosum Leprosum: A Case Report | |
| Hoang et al. | Zinc Iodide-Dimethyl Sulfoxide Composition in Treatment of Chronic Respiratory Diseases | |
| HK40100879A (en) | Methods for treating heterotopic ossification |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130312 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130312 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140311 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141125 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150225 |
|
| A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150527 |
|
| A912 | Removal of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20150731 |